Galecto

About:

Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.

Website: http://galecto.com/

Top Investors: OrbiMed, Seventure Partners, Cormorant Asset Management, Bristol-Myers Squibb, Novo Holdings

Description:

Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.